RESUMO
Background: Gonadotropin-releasing hormone analog [GnRHa] therapy is used in central precocious puberty [CPP] worldwide and it is the treatment of choice for this condition
Many of the previous studies concerning the effect of gonadotropin-releasing hormone analog [GnRHa] therapy on height. Much less attention has been paid to changes in body weight. However, concerns have been expressed that CPP may be associated with increased body mass index [BMI] both at initial presentation and during GnRH agonist treatment, but it is controversial in some studies
Methods: We have retrospectively reviewed 52 female patients that the majority of them had CPP. We assessed height, height SDS, weight, weight SDS, BMI and BMI SDS. All patients were treated with GnRHa over 12 months. The variables were evalu-ated at 0, 6 and 12 months after initiation of treatment. 8 girls received growth hormone concomitantly. Also bone age and sexual maturity were measured. Bone age was assessed according to the Greulich-Pyle method and sexual maturation was classified according to the Marshall-Tanner method
Results: Before the initiation of therapy, the girls had a mean BMI SD score for chronological age of 0.80+/- 1.18 after 6 months of therapy BMI SDS was 0.82+/- 1.15 and after 12 months was 0.82+/-1.28 the P value is 0.909 and it is not The P= 0.66 and it is not statistically significant. Eight girls received growth hormone statistically significant. Height SD score for chronological age was 0.41+/- 1.65 before the initiation of therapy and was 0.4+/-1.65 after 6 months and 0.43+/- 1.60 after 12 months of therapy
concomitantly, in this group increasing height SDS is statistically significant P= 0.044 but increasing BMI SDS is not significant
Conclusion: Gonadotropin-releasing hormone analog [GnRHa] therapy in central precocious puberty [CPP] is safe for BMI and increasing of BMI is not significant, long- term follow-up study is required to elucidate whether GnRHa treatment affects adult obesity. Using growth hormone concomitantly, the effect on increasing height is significant
RESUMO
Acute gastroenteritis is a major cause of morbidity and mortality among children in developing countries. Rotaviruses are recognized as the most common etiologic factors of gastroenteritis. In this study, we determined the epidemiologic features, clinical symptoms and molecular structure of rotavirus VP4[P] genotypes in children with acute diarrhea in Bahrami Hospital in Tehran Iran, during 2009 for justifying the routine use of rotavirus vaccines in children. One hundred fifty fecal samples from 150 children with acute diarrhea in Bahrami Pediatric Hospital in Tehran, Iran were collected from January to December 2009. The patients' mean age was 20.90+18.19 years [ranging from 1 month to 14 years]. Fecal samples were transported on ice to the laboratory of virology department of Pasture Institute of Iran. The demographic and clinical data for each case were entered in an author-devised questionnaire. Group A rotavirus was detected by dsRNA-PAGE. Subsequently, rotavirus genotyping [VP4] was performed by semi-nested multiple RT-PCR and the phylogenetic tree of the Rotavirus nucleotides was constructed. The data were analyzed by statistical tests including Wilcoxon signed and Mann-Whitney U. Rotavirus was isolated in 19.3% of the samples, more than 90% of which had long RNA patterns. The predominant genotype [VP4] was P[8] [86%] and other genotypes respectively were P[6] [6.9%] and P[4] [6.9%]. A high prevalence of the P[8] genotype was found to be the cause of acute diarrhea. The analysis of P[8] genotype sequence showed a high level of similarity of the virus in this study with those of other Asian countries